Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
11 August 2023 - 12:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
(Amendment No.   )
Filed
by the Registrant x
Filed
by a Party other than the Registrant ¨
Check the appropriate box:
¨
Preliminary Proxy Statement
¨
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e) (2))
¨
Definitive Proxy Statement
x
Definitive Additional Materials
¨
Soliciting Material Pursuant to Section 240.14a-11 (c) or Section 240.14a-12
NEUBASE THERAPEUTICS, INC.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement,
if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
x
No fee required.
¨
Fee paid previously with preliminary materials.
¨
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
| NeuBase Therapeutics, Inc.
Important Notice Regarding the Availability of
Proxy Materials for the Stockholders Meeting to
be Held on September 28, 2023
For Stockholders of Record as of
August 4, 2023
Have the 12 digit control number located in the shaded box above available
when you access the website and follow the instructions.
When requesting via the Internet or telephone you will need the 12 digit
control number located in the shaded box above.
* If requesting material by e-mail, please send a blank
e-mail with the 12 digit control number (located above)
in the subject line. No other requests, instructions OR
other inquiries should be included with your e-mail
requesting material.
NeuBase Therapeutics, Inc.
Meeting Type:
Date:
Time:
Place:
Annual Meeting of Stockholders
Thursday, September 28, 2023
8:30 AM, Eastern Time
Annual Meeting to be held live via the Internet - please visit
www.proxydocs.com/NBSE for more details.
You must register to attend the meeting online and/or participate at www.proxydocs.com/NBSE
SEE REVERSE FOR FULL AGENDA
INTERNET
www.investorelections.com/NBSE
TELEPHONE
(866) 648-8133
* E-MAIL
paper@investorelections.com
To order paper materials, use one of the following methods.
For a convenient way to view proxy materials and VOTE go to
www.proxydocs.com/NBSE
If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There
is no charge to you for requesting a copy. In order to receive a paper package in time for this
year's meeting, you must make this request on or before September 18, 2023.
This communication presents only an overview of the more
complete proxy materials that are available to you on the Internet.
This is not a ballot. You cannot use this notice to vote your shares.
We encourage you to access and review all of the important
information contained in the proxy materials before voting.
To view the proxy materials, and to obtain directions to attend the
meeting, go to: www.proxydocs.com/NBSE
To vote your proxy while visiting this site, you will need the 12
digit control number in the box below.
Under United States Securities and Exchange Commission rules, proxy
materials do not have to be delivered in paper. Proxy materials can be
distributed by making them available on the Internet.
P.O. BOX 8016, CARY, NC 27512-9903
Meeting Materials: Notice of Meeting, Proxy Statement and Annual Report on Form 10-K |
| NeuBase Therapeutics, Inc.
Annual Meeting of Stockholders
PROPOSAL
1. To elect one Class III director, nominated by our Board of Directors, to serve until our 2026 Annual Meeting of Stockholders and until his
successor is duly elected and qualified;
1.01 Franklyn G. Prendergast, M.D., Ph.D.
2. To ratify the selection of Marcum LLP ("Marcum") as our independent registered public accounting firm for the fiscal year ending December 31,
2023;
3. To conduct an advisory (non-binding) vote on executive compensation; and
4. To approve an amendment and restatement of the Company's Amended and Restated Certificate of Incorporation, as amended, to reflect
Delaware law provisions allowing officer exculpation.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE:
FOR ON PROPOSALS 1, 2, 3 AND 4 |
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
Von Mai 2023 bis Mai 2024